The Motley Fool
Johnson & Johnson vs. Pfizer: Which Healthcare Stock Is a Better Buy for 2027?
• J&J's diversified drug-and-medtech model contrasts with Pfizer's oncology/obesity pivot
• J&J has higher revenue growth, net income, and a 60+ year dividend streak
• Pfizer trades cheaper but carries more legal, pricing, and patent-cliff risk
Johnson & Johnson (JNJ) and Pfizer (PFE) represent two different paths in healthcare investing. J&J relies on a dual-engine model of innovative medicine and medtech, with partners like Genmab (GMAB) and AbbVie (ABBV). Over the trailing twelve months, J&J posted revenue near $99.3 billion (up ~7.8%) and net income of about $16.1 billion, with a 0.6 debt-to-equity ratio and ~$19.7 billion in free cash flow.
Pfizer is pivoting toward oncology and obesity drugs, including oral weight-loss treatments to rival Eli Lilly (LLY), after acquisitions like Seagen. Trailing-twelve-month revenue reached ~$63.6 billion (up ~1.3%), with net income of roughly $4 billion, a 0.8 debt-to-equity ratio, and ~$9.1 billion in free cash flow.
J&J faces talc-related litigation (a $5.5 billion settlement offer), drug-pricing pressure, and the Stelara patent cliff. Pfizer faces Depo-Provera and Chantix litigation, Inflation Reduction Act pricing pressure on drugs like Eliquis and Ibrance, generic competition, and integration risk from Seagen.
Pfizer trades far cheaper (forward P/E of 9 vs. 24, P/S of 2.5 vs. 6.5), reflecting market skepticism about its earnings outlook. Both stocks have lagged the S&P 500 (^GSPC) over the past decade, with Pfizer actually posting a loss. Despite slower growth, J&J's maturity, 60+ year dividend growth streak, and larger absolute payout make it the more attractive pick over Pfizer for 2027.
November 22, 2026 at 8:05 AMPFEJNJGMABABBVLLY